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spreadsheet. The time horizon was 6 months.
Outcomes assessed in the review
The epidemiological and effectiveness model parameters assessed in the review were seroprevalence rates of immunity against hepatitis A and B, vaccination success rates, and compliance rates for college students only.
Study designs and other criteria for inclusion in the review
No criteria were reported. There was no evidence that a systematic review had been undertaken.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Two clinical trials were included in the analysis of vaccination success rates. Three studies were included in the analysis of compliance.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
For the bivalent vaccine, 93.6% of vaccinees gained hepatitis A protection after one dose, 99.0% after two doses, and 99.9% after three doses.
For the bivalent vaccine, 29.7% of vaccinees gained hepatitis B vaccination after one dose, 77.4% after two doses, and 98.2% after three doses.
For college students, the compliance with the first vaccine dose (if deferred) was 85%. The compliance with subsequent vaccine doses was 83% at month 1 and 80% at month 6.
For patients in STD clinics, the hepatitis B seroprevalence was assumed to be 10% among those aged 25 years and 15% among those aged 35 years.
For prisoners, the hepatitis B seroprevalence was assumed to be 25% among those aged 25 years and 35% among those aged 35 years. The authors made several assumptions on the pre-vaccination immunity, on vaccine series compliance, and on vaccine protection.
Methods used to derive estimates of effectiveness

Estimates of effectiveness and key assumptions
The authors assumed that college students, military recruits and travellers were at normal age-specific risk of prior hepatitis A or B infection, and that their risks of prior hepatitis A and B infection were independent. The authors assumed that anti-HBc-negative prisoners and STD clinic patients were at normal age-specific risk of hepatitis A immunity, and that those who were anti-HBc positive were at twice the normal risk.
The authors assumed 100% compliance with the first vaccine doses. For military recruits, they assumed 100% compliance with subsequent vaccine doses, while for prisoners, they assumed 95% compliance with subsequent doses. The authors assumed that for patients in STD clinics, the completion rates were 67% as great as those for adults in general. They also assumed that compliance rates for travellers fell midway between those for college students and STD clinic patients.
For the 1,440 El U hepatitis A vaccine dose, the authors assumed that 98.1% of recipients were protected after one dose and 99.3% after two doses.
Considering the hepatitis A protection with a 720 El U dose at month 1 and a 1,440 El U dose at month 6, the authors assumed that the second dose increased the proportion protected from 93.6 to 99.0%.
Measure of benefits used in the economic analysis
The measure of benefits used was the number of vaccine protections conferred.
Direct costs
The direct costs of the health system were included. These were for serology, vaccine acquisition and administration. Administration costs were based on private sector and public sector prices. The base year of the cost analysis was 2002.
All the costs were adjusted to 2002 levels using the Consumer Price Index for Medical Care. It would appear that the resource quantities have been derived using actual data. Several assumptions about the costs were made. Military recruits, prisoners and STD clinic patients were assumed to receive publicly purchased vaccines. Travellers were assumed to receive vaccines purchased in the private sector. The administration costs of the vaccine for college, STD and travel medicine settings were assumed to be $11.13 per dose. The authors assumed that the costs would be 50% less in military and prison settings.
Statistical analysis of costs
No statistical analysis of the costs was performed.
Indirect Costs
The indirect costs were not included.
Currency
US dollars ($).
Sensitivity analysis
One-way sensitivity analyses were conducted. The serology and administration costs were individually increased and decreased (+/-33% and +/-67%).
